- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06573294
악성 고형 종양에서 GEN1057의 안전성 및 항종양 활성을 평가하기 위한 시험
악성 고형 종양이 있는 피험자에서 GEN1057의 안전성과 항종양 활성을 평가하기 위한 최초의 인간 대상 공개 라벨 용량 증량 시험
The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer.
Trial details include:
- The trial duration for an individual participant will be up to approximately 11 months.
- The treatment duration for an individual participant will be up to approximately 4 months (the duration of treatment may vary for each participant) and the follow-up duration for an individual participant will be approximately 6 months.
Participation in the trial will require visits to the site. All participants will receive active drug; no one will be given placebo.
연구 개요
상세 설명
The trial is a first-in-human (FIH) open-label, multicenter, multinational safety trial.
The dose escalation will evaluate different dose levels by assessing safety, tolerability, and early efficacy signals to determine the expansion dose(s) of GEN1057 as monotherapy, as well as characterizing the pharmacokinetic (PK) profile and immunogenicity in participants with malignant solid tumors who have metastatic or advanced disease.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- SCRI Oncology Partners
-
-
Texas
-
San Antonio, Texas, 미국, 78229
- South Texas Accelerated Research Therapeutics, LLC
-
-
-
-
-
Madrid, 스페인, 28050
- Start Madrid Centro Integral Oncologico Clara Campal CIOCC
-
-
Barcelona
-
Barcelona, Barcelona, 스페인, 08035
- Hospital Universitari Vall d'Hebron
-
-
-
-
-
Tokyo, 일본
- National Cancer Center, Tsukiji 5-1-1
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Advanced and/or metastatic malignant solid tumors, who have progressed on standard of care therapy for whom there is no available standard therapy likely to provide clinical benefit, or who are not candidates for available therapy, and for whom experimental therapy with GEN1057 may be beneficial, in the opinion of the investigator.
- Be at least 18 (or the legal age of consent in the jurisdiction in which the trial is taking place) years of age.
- Have measurable disease according to RECIST v1.1.
- Have Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 at screening and on C1D1 pretreatment. Note: If screening ECOG PS is assessed within 3 days prior to C1D1, ECOG PS does not need to be reassessed at C1D1.
- Have a life expectancy of ≥3 months.
Key Exclusion Criteria:
-
Has been exposed to any of the following prior therapies/treatments within the specified timeframes:
- Treatment with an investigational anticancer agent within 28 days or for systemic therapies within 5 half-lives of the drug, whichever is shorter, prior to trial treatment administration.
- Treatment with an investigational drug, including investigational vaccines within 28 days before the planned first dose of trial treatment.
- Prior treatment with live, attenuated vaccines within 28 days prior to initiation of GEN1057. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live, attenuated vaccines and are not allowed. Experimental and/or nonauthorized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations are not allowed.
- Used an invasive investigational medical device within 28 days before the planned first dose of trial treatment.
-
Has clinically significant toxicities from previous anticancer therapies that have not resolved to baseline levels or to grade 1, except for anorexia, hyperthyroidism, hypothyroidism, and peripheral neuropathy, which must have recovered to ≤ grade 2. There is no limitation for alopecia and hearing impairment from previous therapies.
-
Has known, symptomatic brain metastases. Asymptomatic brain metastases are allowed provided that they have been treated, have been stable for >28 days as documented by radiographic imaging, and do not require prolonged (>14 days) systemic corticosteroid therapy.
-
Has a past or current malignancy other than inclusion diagnosis.
Note: Other protocol-defined inclusion and exclusion criteria may apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: GEN1057 단독요법
|
Intravenous (IV) infusion IV infusion/orally by mouth. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
치료로 인한 부작용(AE)이 발생한 참가자 수
기간: 첫 투여부터 안전성 추적기간 종료까지(약 5개월)
|
첫 투여부터 안전성 추적기간 종료까지(약 5개월)
|
|
|
Number of Participants With Dose Limiting Toxicities (DLTs)
기간: Up to 21 days
|
DLTs will be graded for severity according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), v5.0. |
Up to 21 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
GEN1057의 최대 혈장 농도(Cmax)
기간: 치료 종료(약 4개월)까지 여러 시점에서 투여 전 및 투여 후
|
치료 종료(약 4개월)까지 여러 시점에서 투여 전 및 투여 후
|
|
|
GEN1057의 Cmax(Tmax)에 도달하는 시간
기간: 치료 종료(약 4개월)까지 여러 시점에서 투여 전 및 투여 후
|
치료 종료(약 4개월)까지 여러 시점에서 투여 전 및 투여 후
|
|
|
GEN1057의 0시간부터 마지막 정량 가능 샘플(AUC0-last)까지 농도-시간 곡선(AUC) 아래 영역
기간: 치료 종료(약 4개월)까지 여러 시점에서 투여 전 및 투여 후
|
치료 종료(약 4개월)까지 여러 시점에서 투여 전 및 투여 후
|
|
|
GEN1057의 반감기(t1/2)
기간: 치료 종료(약 4개월)까지 여러 시점에서 투여 전 및 투여 후
|
치료 종료(약 4개월)까지 여러 시점에서 투여 전 및 투여 후
|
|
|
플라즈마로부터 GEN1057의 클리어런스(CL)
기간: 치료 종료(약 4개월)까지 여러 시점에서 투여 전 및 투여 후
|
치료 종료(약 4개월)까지 여러 시점에서 투여 전 및 투여 후
|
|
|
Number of Participants with Anti-drug Antibodies (ADAs) to GEN1057
기간: Up to approximately 11 months
|
Serum samples will be screened for ADAs binding to GEN1057 and the titer of confirmed positive samples will be reported. |
Up to approximately 11 months
|
|
Objective Response Rate (ORR)
기간: Up to approximately 11 months
|
The ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) based on response evaluation criteria in solid tumors (RECIST) version (v) 1.1 as assessed by the investigator. |
Up to approximately 11 months
|
|
Duration of Response (DOR)
기간: Up to approximately 11 months
|
DOR is defined as the time from the first documentation of response (CR or PR) to the date of progressive disease (PD) or death, whichever occurs earlier based on RECIST v1.1 as assessed by the investigator. |
Up to approximately 11 months
|
|
Time to Response (TTR)
기간: Up to approximately 11 months
|
TTR is defined as the time from Cycle 1 Day 1 (C1D1) to the first documentation of objective response (CR or PR) in participants achieving PR or CR based on RECIST v1.1 as assessed by the investigator. |
Up to approximately 11 months
|
|
Disease Control Rate (DCR)
기간: Up to approximately 11 months
|
DCR is defined as the percentage of participants with BOR of CR, PR, or stable disease (SD) based on RECIST v1.1 as assessed by the investigator. |
Up to approximately 11 months
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Study Official, Genmab
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .